Statute Details
- Title: Healthcare Services (Cord Blood Banking Service) Regulations 2021
- Act Code: HSA2020-S1037-2021
- Type: Subsidiary legislation (SL)
- Authorising Act: Healthcare Services Act 2020 (Act 3 of 2020)
- Enacting power: Section 57 of the Healthcare Services Act 2020
- Citation: No. S 1037
- Commencement: 3 January 2022
- Status / version: Current version as at 27 March 2026 (with amendments, including S 389/2023 effective 26 June 2023)
- Regulatory focus: Licensing compliance framework for cord blood banking services, including governance, quality systems, donor consent, testing, processing, storage, distribution, records, and continuity of operations
- Key provisions (from extract): Definitions (s 2); application and precedence (s 3); Clinical Governance Officer qualifications (s 4); quality management system (s 5); safety programme and PPE (ss 8A–8C); consent and counselling (s 9); evaluation/screening and testing (ss 10–11); collection and processing/quarantine (ss 12–13); suitability and distribution (ss 14–16); exceptional infectious disease distribution (s 17); re-identification and notification (s 19); records and transplant information (ss 21–22); continuity and outsourcing (ss 23–24); price transparency (s 25); offence (s 26); Schedule infectious diseases for which the mother must be tested
What Is This Legislation About?
The Healthcare Services (Cord Blood Banking Service) Regulations 2021 (“Cord Blood Banking Regulations”) set out detailed regulatory requirements for licensed cord blood banking services in Singapore. In plain language, they require cord blood banks to run their operations in a way that protects three groups: (1) the infant donor and the mother of the infant donor, (2) recipients who may receive cord blood for treatment, and (3) the integrity and reliability of the cord blood product itself—its safety, quality, potency and viability.
The Regulations sit alongside the Healthcare Services Act 2020 and the Healthcare Services (General) Regulations 2021. They do not replace the general licensing framework; rather, they add specialised rules for cord blood banking. This includes governance structures, quality management systems, safety programmes, donor consent and counselling, donor evaluation and infectious disease testing, laboratory testing and quarantine controls, rules for distribution (including exceptional circumstances), and obligations for records, information disclosure, continuity of operations, outsourcing controls, and price transparency.
For practitioners, the Regulations are best understood as a compliance blueprint: they translate the Act’s licensing objectives into operational duties that can be audited, enforced, and—where necessary—used to determine whether a licensee has met statutory standards of care and safety.
What Are the Key Provisions?
1. Definitions and regulatory scope (ss 2–3). Section 2 defines core terms such as “cord blood,” “infant donor,” “mother,” “recipient,” “transplant,” and “incidental finding.” “Incidental finding” is particularly important: it captures observations or results that are potentially significant for the donor’s health or reproductive importance but are not related to the purpose of the examination or test. This definition underpins later duties on re-identification and notification.
Section 3 provides the Regulations’ relationship with the Healthcare Services (General) Regulations 2021. Unless expressly provided otherwise, the cord blood Regulations apply in addition to the general regulations and prevail in case of inconsistency to the extent the matter relates to an applicable licensee. This precedence clause matters in disputes about which set of rules governs a particular compliance issue.
2. Clinical Governance Officer (s 4). The Regulations require a suitably qualified Clinical Governance Officer for a cord blood banking service. The officer must be a fully registered medical practitioner and a specialist in haematology, with at least five years’ relevant experience. The experience must relate to areas such as haematopoietic stem cell transplant, transfusion medicine (specifically donor assessment/screening/evaluation), blood banking, cord blood banking, or other approved activities. Practically, this provision is designed to ensure that governance is anchored in clinical expertise and not merely administrative oversight.
3. Quality management system (s 5). Section 5 is a cornerstone. It obliges the licensee to establish and maintain an effective quality management system covering: (a) safety of infant donors, mothers, and recipients; (b) safety, quality, potency and viability of cord blood collected, tested, processed, stored and distributed; and (c) proper collection, testing, processing, storage and distribution. The quality system must include investigation of occurrences/complaints, identification and implementation of corrective and preventive actions, compliance measures with the Act and regulations, and quality control measures across the cord blood lifecycle.
Although the extract truncates the remainder of section 5, the structure indicates a classic “quality system” model: detect weaknesses, investigate, correct, prevent recurrence, and ensure ongoing compliance. For counsel, this section provides a framework for assessing whether a licensee’s internal processes are sufficiently robust to meet statutory expectations.
4. Safety programme and protective equipment (ss 8A–8C). The Regulations introduce a dedicated safety programme requirement. Section 8A requires the establishment of a safety programme; section 8B requires the licensee to ensure personnel comply with it; and section 8C requires that personal protective equipment be provided. These provisions are operational and enforceable: they require more than written policies—they require implementation and compliance by personnel.
5. Consent, counselling, and donor evaluation (ss 9–11). Donor protection is addressed through consent and pre-donation counselling (s 9). The Regulations also require evaluation and screening (s 10) and testing of the infant donor or mother (s 11). The Schedule specifies infectious diseases for which the mother of the infant donor must be tested, reinforcing that infectious disease risk management is a statutory requirement rather than a discretionary laboratory practice.
6. Collection, processing, testing, quarantine, and suitability (ss 12–14). The Regulations regulate the collection of cord blood (s 12) and the processing, testing and quarantine of cord blood (s 13). Quarantine is particularly significant: it implies that cord blood may be held under controlled conditions pending test results or other determinations before it can be released for use or distribution. Section 14 addresses suitability of the recipient of cord blood, indicating that distribution is not simply a product issue; it also involves recipient eligibility and appropriateness for transplant.
7. Storage, distribution, and exceptional infectious disease grounds (ss 15–17). Storage obligations (s 15) ensure that viability and integrity are maintained. Distribution (s 16) governs how cord blood may be provided for transplant. Section 17 creates a narrow pathway for distribution on exceptional grounds where the infant donor or mother suffers from infectious diseases. This is a high-risk area: the Regulations recognise that exceptional clinical circumstances may arise, but they require a controlled legal basis for proceeding despite infectious disease status.
8. Import of processed cord blood (s 18). If a licensee imports processed cord blood, section 18 sets out the regulatory requirements. For cross-border operations, this provision is critical: it ensures that imported products meet Singapore’s safety and quality expectations and that the licensee remains accountable for imported materials.
9. Re-identification and notification; information duties (ss 19–20). Section 19 requires re-identification and notification of the infant donor and mother where abnormal findings or incidental findings are discovered. This is a sensitive compliance obligation: it balances donor privacy with the duty to communicate potentially important health or reproductive information. Section 20 then addresses information about the infant donor and mother of the infant donor, reinforcing that donors have rights to relevant information.
10. Records and transplant information (ss 21–22). Section 21 requires establishment and maintenance of records. Section 22 requires provision of information relating to cord blood distributed for transplant. These provisions are essential for traceability, audit readiness, and continuity of clinical decision-making at the transplant stage.
11. Continuity of operations, outsourcing, and price transparency (ss 23–25). Section 23 requires continuity of operations—ensuring that the service can continue safely and effectively, including during disruptions. Section 24 addresses outsourcing, meaning that if functions are outsourced, the licensee must still ensure compliance and control over outsourced activities. Section 25 requires price transparency, which is particularly relevant for consumer-facing cord blood banking arrangements and for ensuring that pricing practices are not opaque.
12. Offence provision (s 26). Section 26 provides for offences. While the extract does not detail the offence mechanics, the existence of an offence section signals that non-compliance with the Regulations can lead to criminal or regulatory consequences, depending on the statutory enforcement framework under the Act.
How Is This Legislation Structured?
The Regulations are structured as a sequential compliance framework that mirrors the cord blood banking workflow:
(1) Introductory provisions: citation/commencement (s 1), definitions (s 2), application and precedence (s 3).
(2) Governance and systems: Clinical Governance Officer qualifications (s 4), quality management system (s 5), personnel and quality personnel (ss 6–7), facilities/equipment/supplies (s 8), safety programme and PPE (ss 8A–8C).
(3) Donor and product lifecycle: consent and counselling (s 9), evaluation/screening (s 10), testing (s 11), collection (s 12), processing/testing/quarantine (s 13), suitability (s 14), storage (s 15), distribution (s 16), exceptional infectious disease distribution (s 17), import (s 18).
(4) Information, traceability, and operational resilience: re-identification and notification (s 19), information about donors (s 20), records (s 21), transplant information (s 22), continuity of operations (s 23), outsourcing (s 24), price transparency (s 25).
(5) Enforcement: offences (s 26).
(6) Schedule: infectious diseases for which the mother must be tested.
Who Does This Legislation Apply To?
The Regulations apply to a “licensee,” defined as a person holding a licence to provide a cord blood banking service. In practice, this will include cord blood banks operating in Singapore that collect, process, store, and/or distribute cord blood for transplant.
The Regulations also interact with other regulated actors. For example, the definition of “transplanting clinician” refers to medical practitioners employed or engaged by an acute hospital service licensee (or permitted to transplant at approved premises). While the Cord Blood Banking Regulations primarily impose duties on the cord blood banking licensee, transplanting clinicians and acute hospital licensees may be indirectly affected through the information and suitability/distribution framework.
Why Is This Legislation Important?
For practitioners, the Regulations matter because cord blood banking sits at the intersection of clinical risk, laboratory quality, and consumer-facing services. A failure in donor screening, testing accuracy, quarantine controls, or traceability can have downstream consequences for transplant safety and efficacy. The Regulations therefore impose detailed, auditable requirements across the entire service chain.
From an enforcement perspective, the combination of (a) governance requirements (Clinical Governance Officer), (b) system requirements (quality management system, safety programme, PPE), and (c) lifecycle controls (testing, quarantine, suitability, distribution, records) creates a structured basis for regulators to assess compliance. The re-identification and notification duties for abnormal and incidental findings also reflect a statutory commitment to donor welfare beyond the immediate purpose of collection.
Finally, the inclusion of continuity of operations and outsourcing controls recognises that modern healthcare services rely on complex supply chains and service providers. Price transparency further indicates that the regulatory regime is not limited to clinical safety; it also addresses fairness and clarity for customers.
Related Legislation
- Healthcare Services Act 2020 (Act 3 of 2020)
- Healthcare Services (General) Regulations 2021 (G.N. No. S 1035/2021)
- Medical Registration Act 1997
Source Documents
This article provides an overview of the Healthcare Services (Cord Blood Banking Service) Regulations 2021 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.